IN Drug Administration for Procedural Sedation in Children Admitted To

Total Page:16

File Type:pdf, Size:1020Kb

IN Drug Administration for Procedural Sedation in Children Admitted To European Review for Medical and Pharmacological Sciences 2018; 22: 217-222 Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room C. FANTACCI1, G. C. FABRIZIO1, P. FERRARA1, F. FRANCESCHI2, A. CHIARETTI1 1Department of Pediatrics, Catholic University of the Sacred Heart, School of Medicine, Gemelli Hospital Foundation, Rome, Italy 2Institute of Internal Medicine, Catholic University of the Sacred Heart, School of Medicine, Gemelli Hospital Foundation, Rome, Italy Abstract. – OBJECTIVE: Pain relief is a very sometimes be overlooked because pain is often important aspect in Pediatrician’s clinical prac- underestimated in childhood. This is due to the tice. It is often thought that young children, par- common belief that young children, particularly ticularly infants, do not perceive as much pain as infants, do not perceive as much pain as adults adults because of their immature nervous sys- because of their immature nervous system and tem and that untreated pain would not have ad- verse long-term consequences. Instead, it has that untreated pain would not have adverse 1,2 been demonstrated that infants and children ex- long-term consequences . On the contrary, it perience pain in a similar manner to adults. Ma- has been shown that infants and children ex- ny factors, particularly emotional factors, can in- perience pain in a similar manner to adults3. crease the child’s pain perception. Children live Furthermore, high levels of pain in children may with anxiety even minor procedures. This sug- have significant neurophysiological and physio- gests the need for an adequate sedation and the 4,5 way of sedation should be free of pain itself. We logical effects . Inadequately managed pain in believe the route to be followed may be the intra- children can also have detrimental psychological nasal (IN) administration of sedative drugs. consequences, which can in turn lead to higher MATERIALS AND METHODS: We have con- levels of pain during medical treatments. For ex- ducted a brief review of the literature by Pubmed ample, emotional factors – such as elevated anx- about the most commonly used sedative drugs: iety, distress, anger and low mood – can increase sufentanyl, fentanyl, midazolam, ketamine, ni- trous oxide and dexmedetomidine. We have in- the child’s pain perception and make subsequent vestigated in the literature the type of adminis- medical procedures and pain management more tration of IN drugs: drop instillation or by a mu- difficult6,7. In addition, a large-scale early re- cosal atomizer device (MAD). searche found that as many as one third of chil- RESULTS: In our study, it was noted that IN dren who experienced medical procedures for drugs administration is an effective and safe method to reduce anxiety and to deliver anal- diagnosis or treatment showed some evidence of 8 gesia because it is practical and non-invasive. subsequent psychological adjustment problems . Moreover, therapeutic levels of sedatives are Moreover, reports of fear and pain experienced low due to the presence of a rich vascular plex- during medical procedures in childhood are us in the nasal cavity, which communicates with predictive of fear and pain during medical pro- the subarachnoid space via the olfactory nerve 9 and reduce the time of medication delivery, that cedures in young adulthood . is, the onset of action. The use of MAD even Children often live with many anxiety and gives as better bioavailability of drugs. anguish even minor procedures, most notably CONCLUSIONS: IN sedation via MAD is ef- the placement of a venous access, and even more fective and safe and should be one of the first seizure control, laceration repair, dental and oph- choices for procedural sedation in children. thalmologic procedures. Usually, children’s fear Key Words: and anticipatory anxiety increase the likelihood Intranasal sedation, Procedures, Pain, Children. of experiencing more pain and distress during the actual procedures; in addition, children typically Introduction report having overly negative expectations prior to medical procedures, regardless of whether a Pain relief is a very important aspect in Pe- pharmacologic or behavioral pain management diatrician’s clinical practice, although it may intervention will be employed10. Corresponding Author: Claudia Fantacci, MD; e-mail: [email protected] 217 C. Fantacci, G.C. Fabrizio, P. Ferrara, F. Franceschi, A. Chiaretti This entails the need to propose not only ade- quate sedation but also a way of sedation free of pain itself as much as possible11. The benefits of providing adequate proce- dural sedation for children include decreasing patient anxiety and emotional trauma, decreas- ing parental emotional discomfort, and facili- tating ease and/or completion of the procedure. A desirable sedating agent has a rapid onset with short duration of action; it is effective and safe12. In recent years, the use of intranasal (IN) ad- ministration of sedative drugs before perform- ing the procedures has taken hold, because it is a practical and non-invasive route of adminis- tration. Therapeutic levels of sedatives can be reached via IN administration due to the rich Figure 2. With the use of MAD, the drug is delivered via a fine spray over a broad surface area in the nasal cavity, vascular plexus cavity which communicates favoring its absorption. with the subarachnoid space via the olfacto- ry nerve13,14. In the recent past many authors preferred IN midazolam administer by drop Materials and Methods instillation; nowadays many studies investigate new methods such as the use of spray devices. Relevant studies were identified from two A mucosal atomizer device (MAD, Figure 1) sources: a key word search including intranasal, delivers drug via a fine spray over a broad sur- drugs, sedation, children, medication, sufentanil, face area in the nasal cavity (Figure 2). It also fentanyl, midazolam, ketamine, nitrous oxide, reduces sneezing and coughing compared to dexmedetomidine; a review of the references other devices15-17. from each identified article. We included in this Different drugs have been used for IN seda- review only pediatric articles. tion for procedural sedation in children; this review aims to re-evaluate this method of se- dation and the drugs most commonly used for Results its usage. Ketamine Ketamine is usually administered intravenous- ly (IV) or intramuscularly (IM), but it may also be administered nasally18. The dose required to achieve a state of dissociative sedation in children is typically 1.0 to 1.5 mg/kg IV or 3 to 4 mg/kg IM19. When used nasally, the recommended ad- ministration dose is 9 mg/kg18. In 2001, Acworth et al20 compared IN mid- azolam vs. ketamine IV plus midazolam IV in children requiring minor procedures, such as laceration repair or foreign body removal, in the ambulatory setting, and concluded that the combination is higher to IN midazolam alone in terms of speed of onset and consistency of effect. In 2013, Nielsen et al21 studied the association of ketamine with sufentanil administered IN. They did not report any serious adverse events; oxygen saturation and heart rate remained sta- Figure 1. MAD (Mucosal Atomizer Device). ble. The reported adverse effects were mild and 218 IN drug administration for procedural sedation in children admitted to Pediatric Emergency Room mostly related to an unpleasant bitter taste imme- received sufentanil had a marked decreased ven- diately after the administration of the nasal spray, tilatory compliance during the induction of an- which disappeared after drinking. esthesia and had a higher incidence of vomiting during the first postoperative day24. Midazolam The bioavailability of IN route ranges from Nitrous Oxide and Fentanyl 50-83%22. It can be administered orally, nasally, Seith et al26 administered a continuous flow of rectally, IV or IM. In a randomized, double-blind, nitrous oxide of 50 to 70% via a full-face mask in placebo control study, Shapiro et al11 showed that association with a pre-calculated dose of 1.5 µg/ midazolam spray offers relief to children anxious kg of IN fentanyl that was administered through about minor medical procedures, such as inser- MAD26-30. A nitrous oxide alone agent has been tion of a needle in a subcutaneously implanted associated with higher levels of emesis; instead, intravenous port, venous blood sampling and according to Seith et al26, the association with venous cannulation. A double-blind, randomized, IN fentanyl reduces the incidence of vomiting. controlled trial conducted by Rakaf et al22 in 2011 Fentanyl is an opiate analgesic with the most reported a success rate of 91% to 100% for com- evidence to support IN route. It is most used for pleting dental procedures following IN midazol- acute pain management like orthopedic fractures am administration. or burns because it controls at relatively high The dose of intranasal midazolam used in doses the pain. Its usage in pediatric patients has the different studies range between 0.2 mg/ shown comparable effectiveness with the IV ad- kg and 0.4 mg/kg or 0.5 mg/kg11-15. The most ministration31. common adverse effects reported following IN midazolam are burning or irritation in the nose Dexmedetomidine and a bitter taste in the mouth. It can determine Recently, some Emergency Pediatric Depart- respiratory and circulatory depression, but these ments have gained a useful experience of this IN side effects are unlikely when midazolam is medication for short procedures in pediatric out- used as a single drug, while they increase when patient. Intranasal route is more rapidly absorbed it is used with opioids or other sedatives. In in blood stems compared to oral form and it pre- their work, Lane et al12 had 1/205 children who serves the airway reflexes and respiratory drive32. received IN administration of midazolam with Generally, this drug is administered at dose of an adverse event. This was a minor desatura- 2-4 µg/kg. Patel et al33 described an 11-year-old tion episode following ketamine administration girl sedated with 2.4 µg/kg of IN dexmedeto- requiring brief blow by oxygen.
Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2021 (July Update)
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2021 (July update) Afghanistan Bezitramide 1 Codeine 20 000 Cannabis 7 050 Dextropropoxyphene 20 000 Cannabis resin 1 Diphenoxylate 800 Coca leaf 1 Fentanyl 6 Cocaine 15 Methadone 120 000 Codeine 700 000 Morphine 10 000 Codeine-N-oxide 1 Pethidine 2 000 Dextromoramide 1 Pholcodine 5 000 Dextropropoxyphene 170 000 Albania Difenoxin 1 Cocaine 1 Dihydrocodeine 1 Codeine 1 190 000 Diphenoxylate 1 Fentanyl 300 Dipipanone 1 Heroin 1 Ecgonine 2 Methadone 16 500 Ethylmorphine 1 Morphine 7 500 Etorphine 1 Oxycodone 1 500 Fentanyl 17 200 Pethidine 2 500 Heroin 1 Pholcodine 1 600 Hydrocodone 11 000 Remifentanil 10 Hydromorphone 4 000 Sufentanil 2 Ketobemidone 1 Algeria Levorphanol 1 Alfentanil 400 Methadone 110 000 Cannabis 3 Morphine 1 590 000 Cocaine 5 Morphine-N-oxide 1 Codeine 2 500 000 Nicomorphine 1 Etorphine 1 Norcodeine 1 Fentanyl 900 Normethadone 1 Heroin 2 Normorphine 1 Methadone 4 000 Opium 10 Morphine 15 000 Oripavine 1 Oxycodone 4 000 Oxycodone 60 000 Pethidine 3 000 Oxymorphone 1 Pholcodine 1 500 000 Pethidine 50 000 Remifentanil 1 Phenoperidine 1 Sufentanil 50 Pholcodine 1 Andorra Piritramide 1 Cannabis 2 000 Remifentanil 17 000 Fentanyl 100 Sufentanil 10 Methadone 1 000 Thebacon 1 Morphine 500 Thebaine 77 000 Oxycodone 2 000 Tilidine 1 Pethidine 500 Armenia Remifentanil 4 Codeine 3 000 Angola Fentanyl 50 Alfentanil 24 Methadone 22 000 Codeine 21 600 Morphine 8 000 Dextromoramide 188 Thebaine 4 100 Dextropropoxyphene 200 Trimeperidine 1 500 Dihydrocodeine 500 Aruba* Diphenoxylate
    [Show full text]
  • Comprehensive Multi-Analytical Screening Of
    COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA,
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • Queensland Health List of Approved Medicines
    Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.
    [Show full text]
  • List of Participants ...8
    WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTI? ENGLISH ONLY REVIEW OF PSYCHOACTIVE SUBSTANCES FOR INTERNATIONAL CONTROL 26-28 SEPTEMBER 1979 CONTENTS Page Introduction ........................................ 2 Scope of the meeting ......................................... 2 Review of drugs for International Control........,........... 3 Sufentanil ................................................. 3 Tilidine..................................................... 3 Dextropropoxyphene .......................................... 4 Phencyclidine ................................................ 4 Phencyclidine analogues ...................................... 5 Mecloqualone ................................................ 5 Selection of further substances requiring control.. .. , . 6 The need for more and better information.. .. .. .. .. 6 List of participants ....................................... 8 List of background documents.. ............................... 10 Annex 1: Summary of the discussion on Investigation of the Stimulant and Reinforcing Properties of Self-Administration of Phenylethylamine Derivatives isolated from Catha.ed. (Khat).. 11-14 e issue of this document does not constitute Ce document ne constitue pas une publication. al publication. It should not be reviewed, II ne doit faire I'objet d'aucun cornpte rendu ou racted or quoted without the agreement of rdsumb ni d'aucune citation sans I'autorisation de e World Health Organization. Authors alone I'Organisation Mondiale de la Sant6. Les opinions responsible for
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2016 (March Update )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2016 (March update ) Afghanistan Etorphine 10 Codeine 50 000 Fentanyl 10 000 Dextropropoxyphene 1 000 000 Heroin 100 Diphenoxylate 5 000 Hydrocodone 10 000 Fentanyl 6 Hydromorphone 6 000 Methadone 20 000 Ketobemidone 10 Morphine 4 000 Levorphanol 10 Pethidine 80 000 Methadone 40 000 Pholcodine 50 000 Morphine 880 000 Albania Nicomorphine 10 Codeine 70 500 Normethadone 10 Fentanyl 90 Opium 10 Methadone 8 000 Oripavine 10 Morphine 5 500 Oxycodone 29 000 Pethidine 2 500 Oxymorphone 300 Pholcodine 1 300 Pethidine 40 000 Remifentanil 8 Phenoperidine 10 Sufentanil 1 Pholcodine 10 Algeria Piritramide 10 Alfentanil 350 Remifentanil 2 300 Codeine 1 000 000 Sufentanil 10 Etorphine 1 Thebacon 10 Fentanyl 500 Thebaine 45 000 Morphine 9 000 Tilidine 10 Pethidine 3 000 Armenia Pholcodine 1 500 000 Codeine 3 000 Remifentanil 1 Fentanyl 35 Sufentanil 30 Methadone 12 000 Andorra Morphine 6 000 Cannabis 1 500 Thebaine 15 Fentanyl 80 Trimeperidine 1 200 Methadone 1 000 Aruba* Morphine 500 Alfentanil 3 Oxycodone 1 500 Bezitramide 1 Pethidine 500 Cocaine 70 Remifentanil 4 Codeine 85 Angola* Dextromoramide 1 Alfentanil 1 Dextropropoxyphene 85 Codeine 22 500 Fentanyl 130 Dextromoramide 188 Hydrocodone 2 Dihydrocodeine 188 Methadone 150 Fentanyl 23 Morphine 540 Morphine 15 000 Opium 450 Pethidine 20 000 Oxycodone 126 Sufentanil 1 Pethidine 404 Anguilla Piritramide 50 Codeine 500 Remifentanil 19 Fentanyl 1 Ascension Island Morphine 20 Alfentanil 1 Pethidine 300 Fentanyl 1 Antigua and Barbuda* Morphine 1 Cocaine 9 Pethidine 5 Codeine 169 Australia Dihydrocodeine 15 Alfentanil 650 Diphenoxylate 28 Beta-Hydroxyfentanyl 3 Fentanyl 1 Cannabis 10 000 Morphine 6 Cocaine 12 000 Oxycodone 2 Codeine 5 720 000 Pethidine 338 Codeine-N-oxide 3 Remifentanil 1 Conc.
    [Show full text]
  • Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41
    Comparative Effectiveness Review Number 41 Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41 Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10065-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, Tennessee Investigators: Jeff Andrews, M.D. Amanda Yunker, D.O., M.S.C.R. W. Stuart Reynolds, M.D. Frances E. Likis, Dr.P.H., N.P., C.N.M. Nila A. Sathe, M.A., M.L.I.S. Rebecca N. Jerome, M.L.I.S., M.P.H. AHRQ Publication No. 11(12)-EHC088-EF January 2012 This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10065-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]